Is heart failure an endocrine disease? Historically, congestive heart failure (CHF) has often been regarded as a mechanical and haemodynamic condition. However, there is now strong evidence that the activation of neuroendocrine systems, like the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, as well as the activation of natriuretic peptides, endothelin and vasopressin, play key roles in the progression of CHF. In this context, agents targeting neurohormones offer a highly rational approach to CHF management, with ACE inhibitors, aldosterone antagonists and beta-adrenergic blockade improving the prognosis for many patients. Although relevant improvements in clinical status and survival can be achieved with these drug classes, mortality rates for patients with CHF are still very high. Moreover, most patients do not receive these proven life-prolonging drugs, partially due to fear of adverse events, such as hypotension (with ACE inhibitors), gynaecomastia (with spironolactone) and fatigue (with beta-blockers).
Introduction
Congestive heart failure (CHF) is caused by the inability of the heart to maintain the circulation of the blood in response to increases in physiological demand. The pump failure has a variety of clinical manifestations, including dyspnoea, fatigue and oedema, severely limiting everyday activities. The decreased capability of the heart to provide sufficient cardiac output with normal filling pressures is due to pathological changes that reduce the capacity of the ventricles to fill (diastolic heart failure) or to expel blood (systolic heart failure). This cardiac remodelling, which leads to ventricular dilatation and increased wall stress, is induced by cardiac overload and increased peripheral arterial resistance. This process is initiated, maintained and aggravated by neuroendocrine activation. This review examines the involvement of neurohormonal activation in the development and progression of CHF. It provides an overview of pharmacological interventions currently available to block the vicious circle ( Figure 1 ) that perpetuates increased neuroendocrine activation and causes further deterioration in cardiac working conditions, with a special focus on recent advances in the inhibition of the renin-angiotensin-aldosterone system (RAAS).
The neurohormonal system in CHF
A solid base of clinical and scientific evidence now supports the inhibition of neurohormonal activation as a cornerstone of CHF therapy. Under physiological conditions, the RAAS and sympathetic nervous system, working together, ensure that blood pressure responds appropriately to changing stimuli. Factors that reduce blood volume, renal perfusion pressure, or plasma sodium concentration activate these systems to maintain blood pressure, whereas factors that increase these variables tend to suppress activity and decrease blood pressure. In CHF, too, the neurohormonal system is activated, with the RAAS stimulated to produce angiotensin II that, in turn, induces the secretion of norepinephrine.
Along with the activation of the RAAS and the sympathetic nervous system, plasma endothelin and vasopressin become activated. This leads to further increased vasoconstriction of peripheral and pulmonary vessels, and to a further expansion of plasma volume. These factors also increase vascular resistance and thus impose an additional load on the diseased heart. Although initially an adaptive response to diminished cardiac output, these actions themselves contribute, in the longer term, to worsening CHF. The only potentially powerful counteracting system, the natriuretic peptide system (atrial natriuretic peptide [ANP] and brain natriuretic peptide [BNP]), with its diuretic, natriuretic and vasorelaxant properties, loses its effectiveness during the development of CHF. The importance of other vasodilating systems, like the bradykinins and prostaglandins, and adrenomedullin, is still unknown, although acute administration has proven useful. 1 The neurohormonal system is therefore a key player in cardiovascular disease, and one that is ideally suited to targeting by a range of therapies. Clinical trials investigating the effects of endothelin receptor blockade and of the inhibition of endopeptidase, which degrades natriuretic peptides, are underway. Up to now, the most impressive and definitive results have been obtained with agents interacting with the RAAS, namely betablockers and angiotensin converting enzyme (ACE) inhibitors.
The components of the RAAS
The main components of the RAAS and the effects of RAAS activation that can contribute to cardiovascular disease are shown in Figure 2 . These include vasoconstriction, cell growth (leading to cardiac and blood vessel remodelling), sodium and fluid retention, and activation of the sympathetic nervous system. The enzyme renin catalyses the initial step in the RAAS cascade, and has only one natural substrate, angiotensinogen. As its name suggests, renin is produced in the kidney and is secreted into the circulation. Renin is released in response to a range of stimuli and its production can be suppressed by a number of pharmacological agents (Table 1) .
Angiotensinogen, produced mainly by the liver, is cleaved by renin to yield the decapeptide, angiotensin I, which itself has no haemodynamic activity, but is converted to the vasoconstricting octapeptide, angiotensin II, by angiotensin converting enzyme (ACE).
ACE also degrades bradykinin, an effective vasodilator with inflammatory properties, and this and other peptide fragments are believed to be responsible for the ACE inhibitor-induced cough experienced by some patients. In addition, ACE interferes with the metabolism of a number of peptides, including substance P and tachykinin. It is possible that these non-ACE related actions complement the direct vasoconstricting effect produced by angiotensin II. ACE is present in most human tissues and body fluids, and is found in its highest quantities in the vascular endothelium.
Other, non-ACE pathways for the production of angiotensin II also exist ( Figure 2 ); in the myocardium, chymase is probably the most important. This enzyme seems to assume particular significance in mediating cardiac and vascular changes after injury, including those following myocardial infarction when it seems to be upregulated. Another group of angiotensin II-generating enzymes produces angiotensin II directly from angiotensinogen; examples include cathepsin G and chymostatin-sensitive angiotensin II-generating enzyme (CAGE). 2 Because none of these non-ACE pathways is blocked by ACE inhibitors, such agents cannot eliminate all angiotensin II formation. Indeed, there is evidence that plasma levels of angiotensin II return towards pretreatment values, even when ACE inhibition is maintained long-term.
Figure 1
The renin-angiotensin-aldosterone system (RAAS) and its interactions with other endocrine systems, leading to a deterioration in cardiac function.
Figure 2
Synthesis of angiotensin II and mediation of its effects. 
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Angiotensin II -the final effector of the RAAS cascade
The physiological roles of angiotensin II are diverse ( Table 2 ). It is one of the most potent natural vasoconstrictors, increasing peripheral resistance and thereby increasing cardiac pre-and afterload. Angiotensin II also stimulates sodium reabsorption by the proximal tubules of the kidney and promotes the synthesis and secretion of aldosterone, which enhances fluid retention by increasing sodium re-uptake by the distal tubules. This, in turn, contributes to a rise in blood pressure, further increasing cardiac afterload. Aldosterone also potentiates vasoconstriction by other neurohormones. It has recently been implicated in myocardial fibrosis, which compromises the ability of the heart to expand and contract, and has been linked to diastolic dysfunction and to the development of cardiac arrhythmias.
Angiotensin II also stimulates, directly and indirectly, the release of epinephrine and norepinephrine, which are themselves associated with CHF progression.
All known deleterious haemodynamic effects of angiotensin II, whether produced directly by angiotensin II or through neurohormonal activation, are mediated by its binding to highly selective cellsurface receptors. 3 These angiotensin II type 1 (AT 1 )-receptors are therefore an ideal target for pharmacological intervention in CHF. Binding of angiotensin II to the AT 1 -receptor initiates a cascade of intracellular events, including G-protein activation, the formation of inositol triphosphate and diacylglycerol, calcium release from the endoplasmic reticulum and calcium influx through channels in the plasma membrane.The combined action of increased intracellular calcium and diacylglycerol activates protein kinases that phosphorylate intracellular proteins. This changes the structure of these proteins, thereby allowing them to mediate the effects of angiotensin II on the circulatory system.
Even though the signal transduction events are complete within minutes or even seconds, the induced responses to angiotensin II do not only include short-term haemodynamic and renal effects. They also involve intracellular structural changes and, by inducing the expression of specific genes, increase vascular smooth-muscle cell and cardiac myocyte hypertrophy and fibroblast proliferation.
Angiotensin II also binds to the angiotensin II type 2 (AT 2 )-receptor sub-type, which is upregulated in CHF. The precise function of AT 2receptors is not fully understood, 4 but they are thought to be involved in the inhibition of vascular smooth muscle cell and cardiac myocyte growth, probably by inducing apoptosis. Another AT 2specific effect is the induction of bradykinin and nitric-oxide-mediated vasodilation, which is accompanied by production of the second messenger cGMP. Selective blockade of the AT 1receptor leads to an increased circulating level of angiotensin II, which is available to bind to the unblocked AT 2 -receptors. The resulting increased binding of angiotensin II to AT 2 -receptors might thereby contribute to the effects observed with AT 1 -receptor antagonists. 5
Other neurohormones in CHF
A number of other neurohormones have also been implicated in the development and progression of CHF. Like angiotensin II, norepinephrine activates protein kinases involved in cardiac and blood vessel remodelling. Norepinephrine increases cardiac contractility and heart rate, which initially represents a useful adaptive response to reduced cardiac output. Catecholamines, however, are arrhythmogenic, especially in heart failure and this, together with the increased stress placed on the heart by persistent tachycardia and oxygen consumption, aggravates CHF signs and symptoms. Chronic inhibition of beta-adrenergic activation by beta-blockade has been demonstrated to reduce morbidity and mortality significantly in CHF (MERIT-HF, 6 CIBIS-II 7 ). The MERIT-HF study, for example, was stopped early, after it showed that allcause mortality in a group of patients receiving controlled/extended release metoprolol (7.2% per patient-year) was significantly lower than in a group of patients receiving placebo (11.0% per patient-year) (p < 0.0001). 6 The CIBIS-II trial was also stopped early, again after all-cause mortality was found to be significantly lower in patients receiving beta-blockade (11.8%) than in those receiving placebo (17.3%) (p < 0.0001). 7 Indeed, the transition from compensated to decompensated CHF is thought to be related to the overproduction of norepinephrine and angiotensin II. 8 Plasma levels of these two compounds are significantly elevated in patients with CHF. 9 A relationship between impaired left ventricular systolic function and elevated levels of both angiotensin II and norepinephrine has been demonstrated. 10, 11 This association between neurohormonal activation and diminished cardiac function has also been indicated by a significant correlation between exercise tolerance and plasma norepinephrine concentration. 12 ANP and BNP are involved in water and electrolyte homeostasis in CHF and, while both these cardiac hormones are induced in compensated CHF, animal studies suggest that BNP expression is induced to a greater extent than ANP in decompensated CHF. 13 It is also interesting to note that plasma concentrations of norepinephrine 14, 15 and of ANP 14 are increased constitutively in older individualsa factor that might contribute to the increased incidence of CHF in the elderly.
ACE inhibitors: the evidence in CHF
Much of our knowledge of the haemodynamic effects of neurohormones has been derived from studies of ACE inhibitors in patients with CHF. ACE inhibition reduces neurohormonal activation 16, 17 and a number of studies have shown that these agents can significantly reduce morbidity and mortality in severe CHF (CONSENSUS-1 18, 19 ), in moderate CHF (SOLVD [20] [21] [22] [23] ) and after myocardial infarction (AIRE 24 , SAVE 25 ). Since plasma concentrations of angiotensin II return towards their original levels after chronic ACE inhibition, low-dose and high-dose ACE inhibition have been compared in the ATLAS trial, 26 which showed beneficial effects of higher dosages. The results of these studies are considered to be strong evidence for the role of angiotensin II as a mediator of CHF progression. However, since plasma concentrations of angiotensin II were only temporarily and incompletely diminished, it is unknown whether additional inhibition of the RAAS would have further benefit. 3
ACE inhibitor-aldosterone antagonist combinations
Spironolactone is an aldosterone antagonist and potassium-sparing diuretic, and its addition to ACE inhibitor-based CHF therapies further reduces the signs and symptoms of CHF. This has been shown by a pilot study of 42 patients in NYHA classes II or III, who were randomised to receive spironolactone or placebo, in addition to therapy incorporating a loop diuretic and an ACE inhibitor. This addition of spironolactone, 50-100 mg per day, to treatment regimens significantly increased cardiac uptake of norepinephrine and reduced ventricular arrhythmias. 27 Further evidence of the benefits of adding spironolactone to existing ACE inhibitor-based therapies was provided by the Randomized Aldactone Evaluation Study (RALES). This involved 1663 patients with severe CHF (NYHA class III or IV with LVEF < 35%), who were receiving standard regimens comprising an ACE inhibitor, loop diuretic and, in some cases, digoxin. Patients were randomised to receive spironolactone, 25-50 mg, or placebo, for 3 years, in addition to their usual therapy. 28 The RALES study was halted when interim results indicated a 30% risk reduction in mortality among patients receiving spironolactone in addition to standard therapy, compared with those receiving only existing therapy with ACE inhibitors, loop diuretics and digoxin (p < 0.001). 29 In addition, the combination of spironolactone with existing therapy reduced nonfatal cardiac hospitalisations by 30%. These benefits, in addition to those provided by ACE inhibition, were associated with improved endothelial function, with increased bioactivity of the endogenous vasodilator, nitric oxide (NO), and decreased vascular conversion of angiotensin I to angiotensin II. 30 Spironolactone is, however, not well tolerated in clinical practice (as demonstrated by an approximately 10% incidence of gynaecomastia or breast pain in RALES).
Limitations of ACE inhibitors and advantages of AT 1 -receptor blockers
Although ACE inhibitors modulate neurohormone levels, reduce sympathetic tone and produce significant clinical benefits in CHF, the existence of non-ACE pathways for the production of angiotensin II may limit the long-term benefits of ACE inhibitors. This led to the concept of direct angiotensin receptor blockade, which would block angiotensin II-mediated effects independent of its generating pathway. In addition, significant numbers of patients are unable to tolerate ACE inhibition as a result of persistent, dry cough, hypotension and occasional angioneurotic oedema. The fear of ACE-inhibitor associated adverse events may be a principal reason for the disappointing fact that 50-70% of patients with CHF in western countries are not currently treated with an ACE inhibitor. In contrast, AT 1receptor blockers are better tolerated and can block the deleterious actions of angiotensin II, irrespective of its route of formation. These agents, as demonstrated by studies with candesartan cilexetil, are effective in the treatment of hypertension. [31] [32] [33] In contrast to ACE-inhibitors, which tend to decrease plasma levels of angiotensin II, AT 1 -receptor blockers increase angiotensin II formation, thereby stimulating the unblocked AT 2 -receptors, with potentially beneficial effects. AT 1 -receptor blockers are therefore hypothesised to be at least as effective, and possibly more beneficial, than ACE inhibitors in preventing the myocardial hypertrophy and increased peripheral resistance associated with CHF.
ELITE suggested potential benefits of losartan…
The first clinical evidence of the potential benefits of AT 1 -receptor blockade in patients with CHF came from the Evaluation of Losartan in the Elderly (ELITE) trial. 34 This was a study in 722 elderly patients and compared the efficacy and tolerability of losartan with that of captopril. Although ELITE
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September 2000 Volume 1 Supplement 1 28 was not designed as a survival study and was not powered to demonstrate effects on mortality, it did show a significant decrease in all-cause mortality in patients receiving the AT 1 -receptor blocker (mortality: 4.8%) compared with those receiving the ACE inhibitor (mortality: 8.7%).
… that were not confirmed by ELITE II
The follow-up ELITE-II study of 3,152 patients did not, however, show that losartan, 12.5-50 mg once daily, was more effective than captopril, 12.5-50 mg three times daily. The study was designed to test the superiority of losartan and was not powered to demonstrate equivalence in the efficacy of the two agents. 35 Furthermore, the dosing regimens involved comparison of low doses of losartan (mean dose: 42.6 mg) with robust doses of a short acting ACE inhibitor (mean dose of captopril: 122.7 mg). ELITE-II therefore left many questions unanswered.
Large-scale outcome trials in progress
The results of two large-scale outcome trials of the efficacy of AT 1 -receptor blockade in CHF, will be essential in increasing our understanding of the value of AT 1 -receptor blockade in CHF. One of these, the Valsartan Heart Failure Trial (Val-HeFT) compared the potential benefits of valsartan, up to 160 mg twice daily, with those of placebo on time to death or to first CHF-related event in 5010 patients with stable, NYHA class II-IV CHF and impaired left ventricular systolic function (mean LVEF: 26.7%). Most patients (92.3%) were also treated with an ACE inhibitor. The trial ended on May 5, 2000, when 906 deaths had been recorded, and the results will be available in November, 2000.
The other large-scale outcome trial, the Candesartan in Heart Failure -Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme, addresses a number of additional issues (see below).
Modulation of neurohormonal activation with candesartan
Several studies, including the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study and the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE), have shown that candesartan can improve the signs and symptoms of CHF. In addition, candesartan has been shown in randomised studies to modulate neurohormonal activation in CHF.
The double-blind RESOLVD Pilot Study compared candesartan cilexetil alone (4 mg,n = 111; 8 mg, n = 108; or 16 mg, n = 108), and the combination of candesartan cilexetil and enalapril (4 mg + 20 mg, n = 165; 8 mg + 20 mg, n = 167) with enalapril alone (20 mg, n = 109) in patients with documented CHF due to systolic dysfunction. 36 After 43 weeks of treatment, candesartan cilexetil, 4, 8, or 16 mg, was as effective as enalapril, 20 mg, in improving left ventricular function, functional capacity and quality of life. Attenuation of ventricular remodelling, as measured by end-diastolic and end-systolic volumes, was significantly better in patients receiving a combination of candesartan and enalapril, compared with monotherapy with either enalapril or candesartan.The increase in LV end-diastolic volume was diminished from 23 ± 7 mL (enalapril alone) and 27 ± 4 mL (candesartan alone) to 8 ± 4 mL (p < 0.01) with the combination therapy. Aldosterone levels were also reduced in patients receiving candesartan.
Furthermore, BNP levels were diminished in patients receiving candesartan, the greatest reduction occurring in individuals receiving the highest dose, and in those receiving candesartan combined with enalapril. Chronic AT 1 -receptor blockade has a dual effect on natriuretic peptides.As an indicator of improved heart failure, it has been demonstrated to result in chronically decreased plasma levels of natriuretic peptides (ANP, BNP). In addition, angiotensin inhibition facilitates the acute release of ANP in response to acute volume expansion, which is blunted in CHF, thus improving the renal availability of acute water and sodium handling via a new mechanism. 37 This interaction might contribute to the beneficial effects of AT 1receptor blockade in heart failure.
The potential clinical benefits of candesartan in CHF were also demonstrated by the SPICE Pilot Study of patients in NYHA classes II to IV and with impaired LV function (LVEF < 35%), who were intolerant of ACE inhibition. Although not powered to demonstrate outcome differences, SPICE did indicate a trend towards less progression of CHF and rehospitalisation in patients receiving candesartan, compared with those receiving placebo. 38 Despite the fact that all patients entering the study were intolerant of ACE inhibitors, over 80% of patients remained on candesartan therapy throughout the study.
The neurohormonal and haemodynamic effects of candesartan were demonstrated in a double-blind trial, 39 involving 218 patients with NYHA class II or III CHF and impaired LV function (pulmonary capillary wedge pressure, PCWP, > 13 mmHg and LVEF < 40%). Patients were randomised to receive candesartan cilexetil, 2 mg (n = 45), 4 mg (n = 46), 8 mg (n = 39), or 16 mg (n = 44), or placebo (n = 44), once daily for 12 weeks. Mean ejection fraction was approximately 30% and the mean PCWP approximately 18 mmHg, with no significant differences between the groups. Treatment with candesartan lowered PCWP and systemic vascular resistance (SVR) and improved NYHA classification, with a long duration of action with the 8 mg and 16 mg doses. In addition, candesartan seemed to modulate the levels of several neurohormones involved in CHF progression. Plasma renin activity and angiotensin II concentration also increased, while the aldosterone level was reduced, by once-daily dosing. ANP levels were not changed after the first dose, but decreased after chronic treatment. Changes in epinephrine and norepinephrine levels were not significant in this investigation. The effect on renin, angiotensin and aldosterone levels was maintained throughout the whole study period of 12 weeks, indicating a persistent neurohumoral modulation.
The modulating effects of candesartan on neurohormonal activation might, at least in part, contribute to the efficacy of this agent in CHF. The wider clinical significance of the benefits of candesartan, and of its effects on neurohormone levels, are currently under investigation in the large-scale Candesartan in Heart Failure -Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme. This comprises three trials, designed primarily to evaluate the effects of candesartan cilexetil, 4-32 mg once daily, on the combined endpoint of cardiovascular death or hospitalisation for CHF in patients with impaired LV function (LVEF < 40%), as well as in those with preserved LV function (LVEF > 40%). 40 The CHARM Study Programme has almost finished recruitment, with some 7,400 patients randomised. Results will most likely be available in 2002. Further details of this important outcome trial are given in the article by John McMurray, also in this supplement.
Conclusions
Many studies have shown that neurohormonal blockade with ACE inhibitors, spironolactone or beta-blockers can substantially improve symptoms and survival in CHF, although class-specific adverse events often limit the overall clinical value of these agents, as shown by the under-utilisation of these drugs. AT 1 -receptor blockers, such as candesartan, combine efficacy with placebo-like tolerability. AT 1 -receptor blockade therefore has a potentially important role in CHF management. The AT 1 -receptor blocker, candesartan, favourably modulates neurohormonal activation in CHF, and it is hypothesised that this effect might contribute to the efficacy of this drug.The results of the largescale CHARM Study Programme now underway should provide pivotal evidence of the true value of candesartan in CHF, and of its modulation of neurohormonal activation in this debilitating condition.
